预约演示
更新于：2025-04-17
Bromhexine Hydrochloride
盐酸溴己新
更新于：2025-04-17
概要
基本信息
原研机构 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 (1963-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H21Br2ClN2 |
InChIKeyUCDKONUHZNTQPY-UHFFFAOYSA-N |
CAS号611-75-6 |
关联
39
项与 盐酸溴己新 相关的临床试验CTR20244253
吸入用盐酸溴己新溶液改善成人下呼吸道感染疾病黏痰症状的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
CTR20241734
盐酸溴己新片生物等效性试验
CTR20241528
盐酸溴己新片在健康研究参与者中的单剂量、随机、开放、交叉、两周期空腹和餐后人体生物等效性试验
100 项与 盐酸溴己新 相关的临床结果
登录后查看更多信息
100 项与 盐酸溴己新 相关的转化医学
登录后查看更多信息
100 项与 盐酸溴己新 相关的专利（医药）
登录后查看更多信息
1,142
项与 盐酸溴己新 相关的文献（医药）2025-02-01CHROMATOGRAPHIA
Development and Validation of Confirmatory Quantitative and Screening Methods for 63 Prohibited Substances in Horse Urine Using LC–MS/MS
作者: Goktas, Eylem Funda ; Kabil, Erol
Abstract: The number of potentially abused substances in horse racing is very large and it is not easy to analyze the full range.To facilitate the analyses of substances of abuse, a method has been developed for 63 substances in horse urine using liquid chromatog.-tandem mass spectrometry.The developed method has been validated according to the 2021/808/EC and AORC criteria.The horse urine samples were extracted after enzymic hydrolysis via a C8-BCX SPE cartridge with an automated SPE and analyzed by LC-MS/MS.According to the validation study results, the within-laboratory reproducibility CV was no more than 13.9% and the average recoveries ranged from 90.71 to 117.94% for repeatability and reproducibility.The decision limits (CCα) for quant. anal. and detection capabilities (CCβ) for qual. screening were close to the targeted limit for each substance.The results of the present study showed that the method was able to perform quant. analyses of 54 substances and screening analyses of 9 substances (total 63) in horse urine and that the results were valid and applicable.The validated method was successfully applied to five proficiency tests and three suspected samples.
2024-12-01JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
Bidentate bromhexine drug coordination modes with various transition metal ions: Synthesis, characterization, and in vitro antibacterial and anti-breast cancer activity tests
Article
作者: Mahmoud, Nessma Fathi ; Omar, Norhan Refaie ; Sayed, Fatma Nabil ; Mohamed, Gehad Genidy
BACKGROUND:
Bromhexine (BHX) is a mucolytic drug used in treatment the respiratory disorders which are associated with excessive or viscid mucus. Transition metal complexes have made tremendous progress in the treatment of a variety of human ailments, according to reported articles. Transition metal complexes are being developed as medications with a lot of effort. Metal complexes can form a variety of coordination geometries, giving them distinct forms. So, binary metal complexes of bromhexine drug have been prepared to enhance the biological activity and stability of the free drug.
METHODS:
A new series of binary complexes with bromhexine drug (BHX) has been prepared with some transition metal ions namely Cr(III), Mn(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II), and Cd(II). Elemental analyses, FT-IR, mass spectrometry, thermal studies and UV-Vis spectra have been used to characterize and structurally elucidate the produced metal complexes. Antibacterial activity has been tested for the ligand and metal complexes against a variety of pathogenic bacterial species (Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus). In addition, the ligand has been tested for anticancer efficacy against the MCF-7 breast cancer cell line, as opposed to binary metal complexes. The binding orientation or conformation of the free BHX ligand and Co(II) complex in the active region of the protein of crystal structure of Escherichia coli (PDB ID: 3T88) and Pseudomonas aeruginosa (PDB ID: 6NE0) has been performed using molecular docking studies.
RESULTS:
The BHX ligand coupled in neutral bidentate mode to the metal ions, according to FT-IR and 1H-NMR spectral results. The molar conductivity measurements of the complexes in DMF proved the electrolytic nature of all binary complexes. Co(II) complex showed the highest inhibition zone diameter against S. aureus, E. coli and P. aeruginosa. Zn(II) complex had the greatest inhibitory effect against P. aeruginosa and B. subtilis. Also, Cd(II) chelate appeared high efficacy as antibacterial agent against Pseudomonas aeruginosa and Staphylococcus aureus.
CONCLUSION:
All the output data conjugated to confirm the octahedral geometry of the metal complexes. The biological findings revealed that metal complexes can be more active than the free BHX ligand. Against MCF-7 cell line, Cd(II)-L complex is highly active complex (4.95 µg/mL) but BHX free drug is the most active compound (3.96 µg/mL).
2024-11-01Respiratory Investigation
Efficacy and safety of mucolytics in patients with stable chronic obstructive pulmonary disease: A systematic review and meta-analysis
Review
作者: Inaba, Ryunosuke ; Ohnishi, Hiroshi ; Tanimoto, Takuya ; Eitoku, Masamitsu
BACKGROUND:
The efficacy and safety of mucolytics in patients with chronic obstructive pulmonary disease (COPD) and chronic bronchitis or exacerbations of COPD have been reported. We conducted a systematic review and meta-analysis of mucolytics in patients with stable COPD.
METHODS:
Reports from randomized controlled trials to evaluate the efficacy and safety of mucolytics, including ambroxol, bromhexine, carbocisteine, erdosteine, fudosteine, l-methylcysteine, and N-acetylcysteine used in patients with stable COPD were searched for in PubMed, Scopus, Embase, Web of Science, the Cochrane Library, and the Igaku Cyuo Zasshi database.
RESULTS:
Twenty-three reports with ambroxol, carbocisteine, erdosteine, l-methylcysteine, or N-acetylcysteine were included in the review. Mucolytics significantly reduced the rates of exacerbation and hospitalization, shortened the duration of antibiotic use and exacerbations, prolonged the time to first exacerbation, and had a tendency to reduce the occurrence of two or more exacerbations in patients with stable COPD compared to placebo. Mucolytics did not improve mortality, number of lost workdays, scores on St. George's respiratory questionnaire, forced expiratory volume in 1 s, or forced vital capacity. The safety profile of mucolytics was comparable to that of placebo.
CONCLUSIONS:
Mucolytics reduce exacerbations and hospitalizations in patients with stable COPD and have a safety profile comparable to that of placebo.
100 项与 盐酸溴己新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 中国 | 2021-07-06 | |
| 慢性支气管疾病 | 临床3期 | 中国 | 2021-07-06 | |
| 慢性鼻窦炎 | 临床3期 | 中国 | 2021-07-06 | |
| 下呼吸道感染 | 临床3期 | 中国 | 2021-07-06 | |
| 气管支气管炎 | 临床3期 | 中国 | 2021-07-06 | |
| 支气管扩张 | 临床3期 | 中国 | 2021-04-07 | |
| 支气管肺炎 | 临床3期 | 中国 | 2021-04-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 50 | (Control Group) | 淵窪鏇選窪鑰衊憲積餘 = 憲衊憲簾蓋齋蓋襯鹹願 積選淵廠顧鏇選簾鑰壓 (網淵膚膚齋獵築艱艱鏇, 餘鬱繭艱憲憲觸膚齋簾 ~ 淵願觸廠積衊窪鹽願顧) 更多 | - | 2022-04-13 | ||
(Bromhexine Hydrochloride Group) | 艱遞鹹願構鬱衊選願遞(網積製窪蓋齋糧鹽鏇窪) = 蓋範襯糧鏇鏇顧繭廠鹹 齋鹹壓鏇齋簾艱糧鹹鑰 (餘膚繭齋鬱膚繭淵衊構, 鬱顧醖繭壓衊鏇窪衊窪 ~ 廠壓網構獵鏇餘蓋鑰醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用